Literature DB >> 18756852

Adherence to highly active antiretroviral therapy (HAAT) at a Federal Medical Centre.

V N Shaahu1, T O Lawoyin, A O Sangowawa.   

Abstract

Highly active antiretroviral therapy (HAART) has proved effective in prolonging survival and improving the quality of life of the people living with HIV/AIDS (PLWHA). For the successful treatment of HIV infection, at least 95% adherence to HAART is required. This study sought to assess adherence to HAART and to identify factors enhancing adherence within the study population. The study was a descriptive cross-sectional survey of 428 patients attending the antiretroviral (ARV) clinic of the Federal Medical Centre, Makurdi. Self-reported adherence and other data were collected using an interviewer-administered questionnaire. Data were analysed using SPSS 11.0 and Epi6; and were exported into Systat 11 for multivariate logistic regression. There were 151 (35.3%) males and 277 (64.7%) females. The mean age was 36.7 +/- 9.6 years. Self-reported adherence rate was 268 (62.6%). The factor most predictive of adherence to HAART was availability of ARVs [OR = 5.2; 95% confidence interval 3.1-8.6; p < 0.001], followed by the ability to afford regular visits to the ARV clinic [OR = 1.7; 95% confidence interval 1.04-2.8; p = 0.034]. A recent diagnosis of HIV made less than 3 years prior to the study period was also significantly associated with adherence to HAART (chi2 = 8.94; p = 0.003). Availability of ARVs and ability to afford to regularly visit the clinic among other factors, positively influenced adherence to HAART among PLWHA. Efforts should be targeted at constant provision of free ARVs and early initiation of therapy for those requiring treatment, as well as ensuring regular adherence-education.

Entities:  

Mesh:

Year:  2008        PMID: 18756852

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  9 in total

1.  Motivational groups support adherence to antiretroviral therapy and use of risk reduction behaviors in HIV positive Nigerian women: a pilot study.

Authors:  Marcia McDonnell Holstad; James E Essien; Ernest Ekong; Melinda Higgins; Ilya Teplinskiy; Modupe Falilatu Adewuyi
Journal:  Afr J Reprod Health       Date:  2012-09

2.  Care of patients on anti-retroviral therapy in kumasi metropolis.

Authors:  S Ohene; E Forson
Journal:  Ghana Med J       Date:  2009-12

3.  Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice.

Authors:  Emmanuel Monjok; Andrea Smesny; Ita B Okokon; Osaro Mgbere; E James Essien
Journal:  HIV AIDS (Auckl)       Date:  2010-03-30

4.  Pattern and determinants of antiretroviral drug adherence among Nigerian pregnant women.

Authors:  S O Ekama; E C Herbertson; E J Addeh; C V Gab-Okafor; D I Onwujekwe; F Tayo; O C Ezechi
Journal:  J Pregnancy       Date:  2012-02-23

5.  Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review.

Authors:  Tessa Heestermans; Joyce L Browne; Susan C Aitken; Sigrid C Vervoort; Kerstin Klipstein-Grobusch
Journal:  BMJ Glob Health       Date:  2016-12-30

6.  Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria.

Authors:  Chukwuma Anyaike; Oladele Ademola Atoyebi; Omotoso Ibrahim Musa; Oladimeji Akeem Bolarinwa; Kabir Adekunle Durowade; Adeniyi Ogundiran; Oluwole Adeyemi Babatunde
Journal:  Pan Afr Med J       Date:  2019-01-07

Review 7.  Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries.

Authors:  Karl Peltzer; Supa Pengpid
Journal:  J Health Popul Nutr       Date:  2013-06       Impact factor: 2.000

8.  Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria.

Authors:  Afiong O Oku; Eme T Owoaje; Olusimbo K Ige; Angela Oyo-Ita
Journal:  BMC Infect Dis       Date:  2013-08-30       Impact factor: 3.090

9.  Self-reported adherence to highly active antiretroviral therapy in a tertiary hospital in Nigeria.

Authors:  Ekiuwa V Eribo; Omokhoa A Adeleye
Journal:  Ghana Med J       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.